Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines

Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., Lockhart, D. J., Valenzano, K. J. · 2009 · Journal of Inherited Metabolic Disease

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding alpha-galactosidase A (alpha-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3). Over 500 Fabry mutations have been reported; approximately 60% are missense. The iminosugar 1-deoxygalactonojirimycin (DGJ, migalastat hydrochloride, AT1001) is a pharmacological chaperone that selectively binds alpha-Gal A, increasing physical stability, lysosomal trafficking, and cellular activity. To identify DGJ-responsive mutant forms of alpha-Gal A, the effect of DGJ incubation on alpha-Gal A levels was assessed in cultured lymphoblasts from males with Fabry disease representing 75 different missense mutations, one insertion, and one splice-site mutation. Baseline alpha-Gal A levels ranged from 0 to 52% of normal. Increases in alpha-Gal A levels (1.5- to 28-fold) after continuous DGJ incubation for 5 days were seen for 49 different missense mutant forms with varying EC(50) values (820 nmol/L to >1 mmol/L). Amino acid substitutions in responsive forms were located throughout both structural domains of the enzyme. Half of the missense mutant forms associated with classic (early-onset) Fabry disease and a majority (90%) associated with later-onset Fabry disease were responsive. In cultured fibroblasts from males with Fabry disease, the responses to DGJ were comparable to those of lymphoblasts with the same mutation. Importantly, elevated GL-3 levels in responsive Fabry fibroblasts were reduced after DGJ incubation, indicating that increased mutant alpha-Gal A levels can reduce accumulated substrate. These data indicate that DGJ merits further evaluation as a treatment for patients with Fabry disease with various missense mutations.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10545-009-1077-0

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Khanna R, 2007, A levels in vitro, in vivo and in healthy volunteers. Abstract 2250/W. Presented at the American Society of Human Genetics Conference, 2007
  2. Schiffmann R, 2008, Abstract 768/T. Presented at the American Society of Human Genetics Conference, 2008

Cited by

See all 180

Metadata

Authors
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., Lockhart, D. J., & Valenzano, K. J.
Affiliations
  • Amicus Therapeutics (United States) (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Benjamin, E. R.
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2009-04-18
Volume
32
Issue
3
Pages
424-440
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2058754026
Cited by
173
References
43
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 8 · 2020: 17 · 2019: 9 · 2018: 15 · 2017: 3 · 2016: 13 · 2015: 6 · 2014: 6 · 2013: 11 · 2012: 11
FWCI
12.85
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Inherited Metabolic Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
Fabry disease, alpha-galactosidase A, 1-deoxygalactonojirimycin, migalastat, pharmacological chaperones, missense mutations, globotriaosylceramide, lysosomal storage disease, enzyme stability, fibroblasts, lymphoblasts, substrate reduction
MeSH terms
alpha-Galactosidase, Fabry Disease, Cell Line, Drug Evaluation, Preclinical, Enzyme Activation, Fibroblasts, Half-Life, Humans, Lymphocytes, Male, Models, Molecular, Up-Regulation, 1-Deoxynojirimycin, Molecular Chaperones, Mutation, Missense

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines. https://app.cochat.ai/papers/10.1007/s10545-009-1077-0
The paper
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., Lockhart, D. J., & Valenzano, K. J. (2009). The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-009-1077-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.